Postpartum Depression: How Common It Is and What Helps

The question

How common is postpartum depression (PPD), and what does the evidence say helps?

Short answer

Roughly 15–19 in every 100 new mothers develop postpartum depression, and roughly 8–10 in 100 new fathers do too — it is one of the most common complications of childbirth [1][2][4][18]. Talk therapy (especially CBT and interpersonal therapy), regular exercise, and antidepressants compatible with breastfeeding all help, and a newer fast-acting pill called zuranolone improved symptoms within 3 days in clinical trials [6][8][10][12]. It is common, it is treatable, and it is not a personal failure.

What the strongest evidence says

How common it is. The best global estimates come from two large meta-analyses of studies using the Edinburgh Postnatal Depression Scale (EPDS), a standard 10-question screening questionnaire. One pooled 291 studies of nearly 300,000 women in 56 countries and found 17.7 in 100 screened positive [1]; an updated analysis of 412 studies put the figure at 19.2 in 100 [2]. Rates vary enormously between countries — from about 3 in 100 in Singapore to over 40 in 100 in South Africa — and are higher where income inequality and maternal mortality are higher [1]. In higher-income countries the figure is closer to 10–15 in 100 [3][5]. One thing to keep in mind: these studies used screening questionnaires, not full clinical diagnoses, so they capture probable depression rather than confirmed cases.

Baby blues are not the same thing. Between 50 and 80 in 100 new mothers get the "baby blues" — tearfulness, mood swings, feeling overwhelmed in the first few days after birth [5]. These are driven by the hormonal crash, exhaustion, and the shock of it all, and they lift within two weeks without treatment. If low mood, tearfulness, or anxiety persist beyond two weeks, that is the line where clinicians start thinking about postpartum depression instead [5]. Severe baby blues are also a known warning sign for developing PPD later, so don't ignore them [5].

Fathers and partners get it too — with a correction. A 2016 meta-analysis pooling 74 studies of 41,480 fathers found that 8.4 in 100 experienced depression between their partner's first trimester and the baby's first birthday, and 13 in 100 at 3–6 months [18]. An older, smaller meta-analysis (43 studies) gave higher figures — 10.4 in 100, and 25.6 in 100 at 3–6 months [4] — so the truth probably sits between the two, and both relied on screening questionnaires rather than diagnoses. Either way, depression in one partner is moderately correlated with depression in the other — this is a family condition, not just a maternal one [4].

Talk therapy works. A 2025 systematic review commissioned by the US Agency for Healthcare Research and Quality and ACOG pooled 44 randomized controlled trials (nearly 6,000 participants) and found that cognitive behavioral therapy (CBT), behavioral activation, and interpersonal therapy (IPT) may all be more effective than usual care at reducing perinatal depression symptoms and increasing recovery [6]. CBT has the largest evidence base; IPT may have a slight edge in some analyses, though rankings differ between reviews [6].

Exercise helps, with a realistic effect size. A meta-analysis of 26 randomized trials found aerobic exercise significantly reduced postpartum depressive symptoms versus standard care [8]. A newer network meta-analysis of 43 trials estimated a standardized effect of −0.37 for aerobic exercise — a small-to-moderate effect, larger in women who were already depressed [9]. Mind–body exercise such as yoga showed the largest effects in that analysis [9]. The catch: many trials were small and short, and "standard care" varied a lot between studies, so take precise numbers with a grain of salt.

Preventing it is possible for high-risk parents. The US Preventive Services Task Force reviewed the evidence and found that counseling (CBT or IPT) offered to pregnant or postpartum people at increased risk — for example, those with a history of depression or current subthreshold symptoms — reduced the likelihood of developing perinatal depression by about 39% [7]. To put that in absolute terms: in a group where 20 in 100 at-risk mothers would otherwise become depressed, counseling might bring that down to roughly 12 in 100 [7]. (Illustrative estimate based on the pooled relative effect.)

Antidepressants and breastfeeding can coexist. Sertraline is the best-studied antidepressant for breastfeeding mothers and is the usual first choice in the UK [11]. The amount reaching the baby through milk is about 0.5–3% of the mother's weight-adjusted dose — well below the 10% level generally considered the concern threshold — and pooled data from over 200 infants found undetectable drug levels in their blood [10][11]. Reported infant side effects (irritability, poor feeding, sleep changes) are rare, subtle, and hard to distinguish from ordinary newborn fussiness [11]. If a medication already worked for you during pregnancy, guidelines generally say to stay on it rather than switch in the fragile postpartum period [11].

A genuinely new option: zuranolone. Zuranolone (Zurzuvae) is the first pill designed specifically for postpartum depression, approved in the US in August 2023 [12]. In two phase-3 trials of women with severe PPD, those on zuranolone improved about 4 points more than those on placebo on a 52-point depression scale (the HAMD-17), with improvement visible within 3 days and effects holding 4 weeks after the 14-day course ended [12]. Common side effects were sedation, dizziness, and headache [12]. (Brexanolone, an earlier IV version, was withdrawn from the US market in 2025 for commercial reasons — zuranolone is the currently available one [12].)

Risk factors. The single strongest predictor is a personal history of depression [7]. Other established risk factors include lack of social support, stressful life events, intimate partner violence, financial strain, a baby with health problems, and an unplanned pregnancy [3][7]. These are associations from observational research — they identify who is more vulnerable, not what causes depression.

Why this matters urgently. In the UK, suicide is the leading cause of direct maternal death between six weeks and one year after birth — deaths from psychiatric causes accounted for 34% of late maternal deaths in the 2021–2023 national surveillance [15].

What it means for the parents (not just the baby)

Your relationship is part of the illness, not collateral damage. When one parent is depressed, the other is more likely to become depressed too — this is a family condition, not just a maternal one [4]. In one small longitudinal study of 80 couples, mothers whose partners were depressed were over four times more likely to have worsened symptoms by six months — the father's mood predicted the mother's trajectory too, not just the other way round (one small study, so take it as a signal, not a settled number) [24]. Depression can also make the relationship itself feel more distant and difficult, and in one study it roughly tripled the odds of sexual problems in the first year (about 15 in 100 depressed mothers vs 10 in 100 non-depressed) — though honestly, we can't always tell which way round that goes: a strained relationship can feed depression just as much as depression strains a relationship [22].

Fathers: the treatment evidence is finally arriving. Until very recently, almost no trial had tested treatment designed specifically for depressed fathers — nearly all treatment trials enrolled mothers [4]. That has started to change. In 2024, the first large trial of a father-focused programme (12 group sessions combining parenting skills, play, and CBT, run by community health workers in Pakistan) found that depressed fathers improved significantly more than those getting usual care — not just in mood, but in parenting stress, quality of life, and how they rated their relationship with their partner [19]. An Australian trial of an online CBT course for fathers found promising results too, though it was small [20]. If you are the non-birthing parent and you're struggling, the old advice ("talk to your GP") now has actual evidence behind it — not just borrowed from studies of mothers.

For mothers: it doesn't always lift within the year. Most women do recover, but across long-term studies the median figure is that about 38 in 100 mothers with PPD are still depressed beyond the baby's first birthday — around 30 in 100 in community studies, up to 50 in 100 among women treated in clinics [21]. And if you're thinking about another pregnancy: roughly 25–50 in 100 women who had PPD get it again after a subsequent birth [23]. That's not a reason to be scared — it is a reason to plan: the same counselling (CBT or interpersonal therapy) that prevents PPD in at-risk parents is exactly what to ask about next time [7]. (Parental-outcomes evidence rating: B.)

What remains uncertain

• Long-term child outcomes. Untreated PPD is associated with effects on children's cognitive and emotional development, but the evidence is observational, and it's hard to separate the depression itself from the stress, poverty, or genetics that travel with it [3].
• Which therapy is best. Network meta-analyses disagree on the ranking of CBT, IPT, and newer formats — partly because trials differ in populations, controls, and follow-up length [6].
• Medication in breastfeeding beyond sertraline. Data on newer drugs (including zuranolone's transfer into breast milk) are thin; most safety data come from small observational studies, not randomized trials [10].
• Paternal PPD treatment. The first large father-targeted RCT (2024) and a small online-CBT trial (2026) show real benefit [19][20], but the evidence base is still thin — replication in more settings is needed.
• Prevalence in low-income countries. Most data come from high- and middle-income settings; the highest reported rates are also where the least research funding goes [1][2].

Benefits and risks in absolute terms

• Therapy: may reduce symptoms and increase recovery versus usual care; no physical side effects; requires time and access, which is a real barrier with a newborn [6].
• Exercise: small-to-moderate symptom reduction; benefits general health and sleep too; effectively free; the main "side effect" is finding the time [8][9].
• Sertraline while breastfeeding: infant exposure 0.5–3% of maternal dose (concern threshold 10%); >200 infants tested, drug undetectable in blood; rare, mild reported effects [10][11]. The alternative — untreated moderate-to-severe depression — carries its own documented risks to parent and baby [3].
• Zuranolone: about 4 extra points of improvement on a 52-point scale versus placebo; benefit visible in days, not weeks; sedation and dizziness are the main side effects; it was tested in women with severe PPD, so it is not a first-line option for mild symptoms [12].
• Postpartum psychosis (different and rare): affects roughly 1–2 in 1,000 births — sudden onset, usually within two weeks, with confusion, mania, or hallucinations. It is a psychiatric emergency requiring same-day hospital assessment [13][16]. Risk is much higher with a personal or family history of bipolar disorder or prior postpartum psychosis [13].

Practical considerations

• The two-week rule is your anchor. Blues in the first two weeks are expected; anything persisting past that deserves a conversation with your GP, midwife, or health visitor — not willpower [5].
• Screening is routine in the UK, but say the truth anyway. NICE guidance says health visitors and other professionals with regular contact should consider asking the two depression identification questions (plus two on anxiety) at every contact in the first year, and sometimes using the EPDS questionnaire for monitoring [13]. Evidence reviews find the EPDS works reasonably well as a screen, though its accuracy shifts with the cutoff and language used [14]. A National Childbirth Trust survey found 22% of mothers at their 6-week check didn't tell the truth about how they were feeling — they "put on a brave face" [17]. The screen only works if you answer honestly.
• Partners: you count. If you're the non-birthing parent and you feel flat, irritable, or detached for weeks — especially around months 3–6 — that's worth raising with your GP too. Paternal depression is real, common, and treatable [4].
• Sleep is treatment-adjacent. You cannot therapy your way out of 3 hours of sleep a night. Protecting one parent's sleep block is one of the most practical interventions available, even if no trial has measured it cleanly.
• Decide about medication with a clinician, not the internet. The breastfeeding-and-medication question has good answers for the common drugs (sertraline, paroxetine); bring your specific medication to your GP or pharmacist rather than stopping abruptly [11].
• This is not about bonding failure. Difficulty bonding is a symptom of depression, not evidence you're a bad parent. It typically resolves as the depression lifts [5].

When to talk to your doctor, midwife, or health visitor

Talk to your GP, midwife, or health visitor promptly if:

• Low mood, tearfulness, anxiety, or irritability persist beyond two weeks after birth [5]
• You can't sleep even when the baby sleeps, or you've lost interest in things you used to enjoy
• You feel unable to care for yourself or the baby, or bonding feels impossible
• You have thoughts of harming yourself or the baby

Seek urgent help — today, not next week — if: you have sudden confusion, racing thoughts, hallucinations, delusions, or mania (possible postpartum psychosis — this needs same-day emergency assessment [13][16]); or you feel you might act on thoughts of harming yourself or your baby.

In the UK: your GP, health visitor, and midwife are the first ports of call; severe cases are referred to specialist perinatal mental health teams, and suspected postpartum psychosis should be assessed within 4 hours of referral [13]. For crisis support: Samaritans on 116 123 (free, 24/7), Shout by texting 85258 (free, 24/7), or NHS 111. The PANDAS Foundation (pandasfoundation.org.uk) offers free support specifically for perinatal mental health. If you or someone else is in immediate danger, call 999 or go to A&E.

References

1. Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and Health Predictors of National Postpartum Depression Prevalence: A Systematic Review, Meta-analysis, and Meta-Regression of 291 Studies from 56 Countries. Frontiers in Psychiatry. 2018;8:248. https://www.frontiersin.org/article/10.3389/fpsyt.2017.00248/full — A
2. Fish Williamson A, Hahn-Holbrook J. Nutritional factors and cross-national postpartum depression prevalence: an updated meta-analysis and meta-regression of 412 studies from 46 countries. Frontiers in Psychiatry. 2023;14. https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2023.1193490/full — A
3. Wang ZY et al. Mapping global prevalence of depression among postpartum women. Translational Psychiatry. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8528847/ — A
4. Paulson JF, Bazemore SD. Prenatal and Postpartum Depression in Fathers and Its Association With Maternal Depression: A Meta-Analysis. JAMA. 2010;303(19):1961–1969. (Summary: https://www.sciencedaily.com/releases/2010/05/100518101618.htm) — A
5. Parental postpartum depression: More than "baby blues". Contemporary Pediatrics (clinical review). https://www.contemporarypediatrics.com/view/parental-postpartum-depression-more-baby-blues — C
6. Couch E et al. Psychological Therapies for Perinatal Depression: Systematic Review and Meta-Analysis. Annals of Internal Medicine. 2025. (Summary: https://www.healio.com/news/womens-health-ob-gyn/20251201/psychological-therapies-show-some-promise-for-treating-perinatal-depression) — A
7. US Preventive Services Task Force. Interventions to Prevent Perinatal Depression: Recommendation Statement. JAMA. 2019. (Summary: http://aafp.org/afp/2019/0915/od1.pdf) — A
8. Cai et al. Effectiveness of aerobic exercise in the prevention and treatment of postpartum depression: Meta-analysis and network meta-analysis. PLOS ONE. 2023. https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0287650 — B
9. Jiang et al. Effectiveness of exercise on perinatal depression and anxiety symptoms: A network meta-analysis and dose–response analysis. Int J Gynecol Obstet. 2026. https://obgyn.onlinelibrary.wiley.com/doi/10.1002/ijgo.70781 — B
10. Orsolini L, Bellantuono C. Using sertraline in postpartum and breastfeeding: balancing risks and benefits. Expert Opinion on Drug Safety. 2018. https://pubmed.ncbi.nlm.nih.gov/29927667/ — C
11. Antidepressant use during breastfeeding (UK clinical review with compatibility table). The Pharmaceutical Journal. https://pharmaceutical-journal.com/article/ld/antidepressant-use-during-breastfeeding — C
12. ACOG Clinical Practice Update: Zuranolone and Brexanolone for Perinatal Depression. Obstetrics & Gynecology. 2025. https://journals.lww.com/greenjournal/fulltext/10.1097/aog.0000000000006093~acog-clinical-practice-update-zuranolone-and-brexanolone-for — B
13. NICE Guideline CG192: Antenatal and postnatal mental health — clinical management and service guidance. https://www.nice.org.uk/guidance/cg192/chapter/Recommendations — A
14. US Preventive Services Task Force. Primary Care Screening for and Treatment of Depression in Pregnant and Postpartum Women: Evidence Report. JAMA. 2016. https://www.uspreventiveservicestaskforce.org/Page/Document/evidence-summary-primary-care-screening-for-and-treatment-of/depression-in-adults-screening1 — A
15. MBRRACE-UK. Data brief: Maternal mortality UK 2021–23 — maternal suicides were the leading cause of deaths between six weeks and one year after the end of pregnancy; deaths from psychiatric causes accounted for 34% of maternal deaths during this period. https://npeu.ox.ac.uk/mbrrace-uk/data-brief/maternal-mortality-2021-2023 — B
16. NICE CG192 Context: "Postpartum psychosis affects between 1 and 2 in 1000 women who have given birth." http://nice.org.uk/guidance/cg192/chapter/Context — A
17. NICE antenatal and postnatal mental health quality standard briefing paper (QS115): a National Childbirth Trust survey found 29% of mothers attending the 6-week postnatal check said their GP did not ask about emotional or mental health issues, and 22% did not tell the truth about how they were feeling — "put on a brave face". https://www.nice.org.uk/guidance/QS115/documents/antenatal-and-postnatal-mental-health-qs-briefing-paper-2 — C
18. Cameron EE, Sedov ID, Tomfohr-Madsen LM, Journal of Affective Disorders 2016;206:189–203 (meta-analysis, 74 studies, 41,480 fathers: 8.4% paternal depression overall, 13.0% at 3–6 months) — [A]
19. Husain I et al., JAMA Psychiatry 2024 (first large RCT of a father-focused PPD programme, Pakistan: improved mood, parenting stress, quality of life, partner relationship) — [B]
20. DadBooster, Journal of Medical Internet Research 2026 (small Australian RCT of online CBT for fathers: promising results) — [C]
21. Vliegen N et al., Harvard Review of Psychiatry 2014 (review: ~38% of mothers with PPD still depressed beyond 12 months; ~30% community, up to 50% clinical samples) — [B]
22. Slomian J et al., Women's Health (London) 2019 (n=325: depression nearly tripled the odds of sexual dysfunction in the first year; 14.8% vs 9.5%) — [C]
23. American Academy of Family Physicians, clinical review 2010 (PPD recurrence 25–50% after a subsequent birth) — [C]
24. Paulson JF, Bazemore SD, Goodman JH, Leiferman JA. The course and interrelationship of maternal and paternal perinatal depression. Arch Womens Ment Health. 2016. https://pmc.ncbi.nlm.nih.gov/articles/PMC4957140/ — [C] Longitudinal study of 80 cohabiting couples, pregnancy to 6 months postpartum: mothers whose partners were prenatally depressed were more than four times more likely to have worsened symptoms; single small study, observational.

Changelog

• 2026-09-09: Delegated agent review for Guille (no external independent reviewer before v1 per 2026-09-09 review model). MBRRACE corrected to current national surveillance (2021–2023: suicide leading cause of late maternal deaths 6 weeks–1 year; psychiatric causes 34%) with a stable NPEU URL — supersedes the 39% wording. Ref 2 upgraded to the published 2023 journal version (Fish Williamson & Hahn-Holbrook, Front Psychiatry). Ref 14 (previously unused) now cited in the screening bullet — all references cited. Paulson, Bazemore & Goodman 2016 "4x" finding verified against the primary (PMC4957140, n=80) and added to reader prose with small-study caveats (new ref 24). Sertraline figures (0.5–3% vs 10% threshold; >200 infants undetectable) spot-verified against a published review. Quin 2024 three-arm trial details verified (n=127, ES 0.56 CBT-I / 0.25 ns bassinet). Egmose and Goldstein 2020 remain unverified — explicitly excluded from publication scope, logged in evidence.md. Approved (rating stays B).
• 2026-09-07: Second-pass editorial review: postpartum psychosis citation upgraded from Wikipedia to NICE (C → A); "brave face" claim re-sourced to the NCT survey with correct citation (new ref 17); minor wording fixes ("most common" → "one of the most common"; brexanolone withdrawal reason).
• 2026-09-08: Parental-outcomes audit applied: corrected paternal prevalence figures (Cameron 2016: 8.4%/13.0%, conflict with Paulson 2010 named explicitly); added father-targeted treatment evidence (Husain 2024, DadBooster), PPD persistence/recurrence data, relationship/sexual-health effects, and MBRRACE suicide-as-leading-cause sentence; added refs 18–23. Topic rating unchanged (B).
• 2026-09-07: Topic created (draft).